-
Trametinib (GSK1120212) Experimental Workflows
2026-09-17
Build reproducible MEK-ERK pathway experiments with Trametinib (GSK1120212), from DMSO stock preparation to phospho-ERK, cell-cycle, apoptosis, and resistance readouts. The workflow also translates recent multi-omics findings into practical assays for comparing B-RAF-mutated and adaptive-resistant cancer models.
-
Light-Inducible RNA Release for Regulated Gene Therapy
2026-09-17
This 2026 Trends in Biotechnology study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that controls therapeutic transgene activity at the translation stage rather than by changing transcription. In mouse models, LIRP-enabled AAV systems used ambient or blue light to regulate metabolic and retinal therapies, illustrating a potentially reversible safety layer for gene and cell-based treatment.
-
Nintedanib (BIBF 1120): Mechanism & Workflow
2026-09-17
Nintedanib, also called BIBF 1120, is an orally active triple angiokinase inhibitor that targets VEGFR, FGFR, and PDGFR signaling. Its research value spans antiangiogenic cancer models, idiopathic pulmonary fibrosis treatment research, and ATRX-stratified receptor tyrosine kinase studies.
-
SCH772984: ERK Control for Radiosensitization
2026-09-16
A translational framework for using SCH772984 to connect ERK1/2 kinase control with radioresistance, ferroptosis biology, mutant-driven tumor models, and pharmacodynamic assay design.
-
Perospirone: Receptor and Kv1.5 Research Workflows
2026-09-15
Perospirone (SM-9018 free base) supports receptor-focused schizophrenia research while enabling a complementary investigation of vascular Kv1.5 channel inhibition. This guide translates its chemistry and pharmacology into practical assay workflows, controls, and troubleshooting strategies for neuropsychiatric and cardiovascular research.
-
Separating Growth Inhibition from Cell Death
2026-09-15
Hannah R. Schwartz’s dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central contribution is a framework for distinguishing proliferative arrest from cell killing, improving the interpretation of potency, timing, and mechanism in cancer biology research.
-
ML133 HCl Workflow for Kir2.1 Research
2026-09-14
ML133 HCl is a selective potassium channel inhibitor for connecting Kir2.1 activity with potassium ion transport, PASMC behavior, and vascular-remodeling signals. This practical guide translates published findings into concentration planning, assay workflows, controls, and troubleshooting decisions.
-
APEX2 Promotes Efficient TERT Expression in hESCs
2026-09-14
A bioRxiv study identifies APEX2, but not its paralog APEX1, as a determinant of efficient TERT expression and telomerase activity in human embryonic stem cells and melanoma cells. RNA sequencing and chromatin immunoprecipitation connect this effect to APEX2 occupancy near repeat elements, especially MIR sequences within TERT intron 2, suggesting a DNA repair–transcription interface.
-
MK-1775: Wee1 Kinase Inhibitor Workflow Guide
2026-09-13
Use MK-1775 to interrogate Wee1-dependent cell-cycle control, distinguish growth arrest from cell death, and test chemotherapy sensitization in p53-deficient cancer models. This workflow emphasizes time-resolved controls, quantitative viability metrics, and troubleshooting for reproducible checkpoint-abrogation studies.
-
Dexamethasone (DHAP) Research Workflows
2026-09-12
Dexamethasone (DHAP) supports controlled studies of NF-κB modulation, stem cell differentiation, autophagy, osteosarcoma growth, and neuroinflammation. This practical guide connects formulation, time-course design, route comparisons, and troubleshooting to improve assay reproducibility.
-
Better In Vitro Drug Response Metrics in Cancer
2026-09-12
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability to clarify whether an anticancer treatment mainly suppresses proliferation, induces cell death, or does both. The framework emphasizes measuring response magnitude and timing separately, improving interpretation of in vitro drug studies and their translation to mechanistic models.
-
Dihydroethidium (DHE): Reliable Superoxide Assays
2026-09-11
This scenario-driven guide explains how Dihydroethidium (DHE), SKU C3807, can support reproducible live-cell superoxide measurements alongside viability, proliferation, and cytotoxicity assays. It covers spectral selection, controls, solvent and storage constraints, interpretation limits, and practical vendor-selection criteria.
-
U0126 for MEK1/2 and Mechanobiology Studies
2026-09-11
Use U0126 to test whether mechanical cues, growth signals, or disease-associated stimuli depend on MEK1/2–ERK activation. Its cell permeability and non-ATP-competitive profile make it especially useful for connecting pathway inhibition with morphology, mineralization, autophagy, and survival readouts.
-
Angiotensin II, Cx43, and M1 Macrophage Polarization
2026-09-10
The reference study connects angiotensin II exposure with M1-like polarization of RAW264.7 macrophages through a connexin 43 and NF-κB/p65 signaling axis. Its combined use of pathway inhibition, Cx43-directed inhibitors, and orthogonal inflammatory readouts provides a useful framework for studying how gap-junction proteins influence macrophage-mediated cardiovascular inflammation.
-
SCH772984 HCl: ERK1/2 Workflow Guide
2026-09-10
SCH772984 HCl enables precise ERK1/2 inhibition across phospho-signaling, proliferation, resistance, and stem-cell chromatin assays. This practical guide connects nanomolar pathway control with workflow design for BRAF- or RAS-driven models and TERT regulation studies.